# Maulik Nanavaty

> Maulik Nanavaty is the chief executive of Anumana, president of Ventures at nference, and chief executive of Vimana. After 16 years at Baxter and 18 years at Boston Scientific, where he led the company’s more-than-$1 billion Neuromodulation unit and previously ran its Japan business, he chose the uncertainty of a young AI company. His public philosophy is practical: advanced medical technology earns adoption only when it fits the way clinicians already work, makes a defensible case to regulators, and faces investors with a candid account of both opportunity and risk.

- **Role:** Chief Executive Officer at Anumana
- **Organizations:** Anumana, nference, Vimana, Boston Scientific, Baxter International, Rani Therapeutics
- **Education:** Ph.D. in Pharmaceutical Sciences, University of Illinois, M.B.A., University of Chicago
- **Known for:** Led Boston Scientific’s more-than-$1 billion global Neuromodulation business., Ran Boston Scientific’s Japan operation after leading its interventional cardiology business there., Joined Anumana as CEO in October 2023 to lead commercialization of its multi-indication ECG-AI platform.

## Career timeline

- **1989-2005** — Held executive roles at Baxter International and Baxter Japan across regulatory, clinical, business development, M&A, medication delivery, biopharmaceuticals and related businesses.
- **2005-2006** — Joined Boston Scientific as Vice President, Corporate Strategy, Boston Scientific Japan.
- **2007** — Served as Vice President and General Manager of Interventional Cardiology in Japan.
- **2007-2011** — Served as President and Representative Director of Boston Scientific Japan.
- **2011-2023** — Led Boston Scientific’s Neuromodulation division as Senior Vice President and President; the global unit grew to more than $1 billion in scale.
- **2016-2025** — Served on the board of Rani Therapeutics; later chaired its compensation committee before resigning in connection with the closing of a private placement.
- **2023-present** — Became Chief Executive Officer and a director of Anumana, President of Ventures at nference, and Chief Executive Officer of Vimana.

## Achievements

- Led Boston Scientific’s more-than-$1 billion global Neuromodulation business.
- Ran Boston Scientific’s Japan operation after leading its interventional cardiology business there.
- Joined Anumana as CEO in October 2023 to lead commercialization of its multi-indication ECG-AI platform.
- Helped guide Anumana’s expansion from diagnostic algorithms into perioperative applications and a Series C investment from Boston Scientific.
- Led Anumana when it was named to Fast Company’s 2026 Most Innovative Companies list in the Medical Devices category.
- Served on Rani Therapeutics’ board from June 2016 until October 2025.

## Latest updates

- **2026-03** — Anumana was named to Fast Company’s 2026 Most Innovative Companies list in the Medical Devices category; Nanavaty credited the team and emphasized clinical validation and everyday usability.
- **2026-01** — Anumana appointed Kevin Ballinger and Jean-Luc Butel to its board as the company prepared to expand commercialization and clinical adoption.
- **2025-10** — Nanavaty resigned from the Rani Therapeutics board, effective with the closing of a private placement, after serving since 2016.
- **2025-07** — In a Medsider interview, Nanavaty explained his workflow-first product philosophy, risk-focused regulatory case and candid approach to fundraising.
- **2025-04** — Anumana announced a Series C investment from Boston Scientific and an expansion into perioperative and acute cardiac care.

## Links

- Website: https://anumana.ai/team/maulik-nanavaty/
- LinkedIn: https://www.linkedin.com/in/mauliknanavaty

---

Profile page: https://yespress.io/maulik-nanavaty
Published by YesPress — https://yespress.io
Last updated: 2026-09-27